8-K: 2seventy bio Reports Q1 2025 Financial Results and Acquisition by Bristol Myers Squibb Nears Completion

2seventy bio announced its first quarter 2025 financial results, highlighting Abecma's U.S. commercial performance and progress toward acquisition by Bristol Myers Squibb (BMS), expected to close in the second quarter of 2025.

Summary

• 2seventy bio reported its financial results for the first quarter ended March 31, 2025.
• The company is in the process of being acquired by Bristol Myers Squibb (BMS), with the acquisition expected to close in the second quarter of 2025.
• The HSR waiting period for the acquisition expired on May 2, 2025, and the tender offer is expected to expire on May 13, 2025.
• Abecma generated $58.6 million in U.S. commercial revenue in the first quarter of 2025, as reported by BMS.
• 2seventy bio ended the quarter with approximately $173.4 million in cash, cash equivalents, and marketable securities.
• Total revenues for the quarter were $22.9 million, compared to $12.4 million for the same period in 2024.
• Research and development expenses were $5.4 million, compared to $43.9 million for the same period in 2024.
• Selling, general, and administrative expenses were $14.9 million, compared to $12.7 million for the same period in 2024.
• Net income was $0.5 million for the quarter, compared to a net loss of $52.7 million for the same period in 2024.
• BMS commenced a tender offer on April 14, 2025, to acquire all outstanding shares of 2seventy bio at $5.00 per share in an all-cash transaction.
• 2seventy bio's Board of Directors unanimously recommended that stockholders tender their shares.
• Following the completion of the transaction, 2seventy bio's common stock will no longer be listed on Nasdaq.
• In light of the announced transaction, 2seventy bio will not be hosting an earnings conference call or providing financial guidance for 2025.

Sentiment

Score: 8

Explanation: The sentiment is positive due to the impending acquisition by BMS, the improved financial performance (net income vs. loss), and the continued revenue generation from Abecma. The acquisition provides a clear path forward for the company and its shareholders.

Positives

• The acquisition by BMS is progressing as expected and is anticipated to close in the second quarter of 2025.
• Abecma continues to generate significant revenue, with $58.6 million in U.S. sales for the quarter.
• The company achieved net income of $0.5 million, a substantial turnaround from the net loss in the same period last year.
• Research and development expenses decreased significantly, contributing to improved profitability.
• The company has a solid cash position with $173.4 million in cash, cash equivalents, and marketable securities.

Negatives

• The company will no longer be listed on Nasdaq following the completion of the acquisition.
• 2seventy bio will not be hosting an earnings conference call or providing financial guidance for 2025 due to the pending acquisition.

Risks

• The acquisition is subject to customary closing conditions, including the tender of a majority of the outstanding shares.
• There is a risk that the expected benefits or synergies of the acquisition will not be realized.
• Legal proceedings may be instituted related to the merger agreement.
• Unanticipated difficulties or expenditures relating to the proposed acquisition could arise, including difficulties in employee retention.

Future Outlook

The acquisition of 2seventy bio by BMS is expected to close in the second quarter of 2025. 2seventy bio will not be hosting an earnings conference call or providing financial guidance for 2025 due to the pending acquisition.

Management Comments

• We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer, said Chip Baird, chief executive officer, 2seventy bio.
• I would like to express my deep gratitude to our current and former team members and more broadly the dedicated community of patients, scientists, providers, partners, and investors who worked tirelessly to deliver more time for patients.

Industry Context

The announcement reflects the ongoing trend of consolidation in the biotechnology industry, with larger pharmaceutical companies acquiring smaller, innovative firms to expand their pipelines and capabilities in areas like cell therapy. BMS's acquisition of 2seventy bio is consistent with this trend, as it allows BMS to strengthen its position in the multiple myeloma treatment market with Abecma.

Comparison to Industry Standards

• Abecma's $58.6 million in U.S. sales can be compared to other CAR-T therapies for multiple myeloma, such as Johnson & Johnson's Carvykti.
• Carvykti generated $152 million in Q1 2024 globally, indicating that Abecma is a smaller player in the market but still a significant contributor.
• The decrease in R&D expenses reflects the shift in focus towards commercialization and the pending acquisition, which is a common pattern for companies in similar situations.
• The cash position of $173.4 million is relatively strong for a company of 2seventy bio's size, providing financial flexibility during the acquisition process.

Stakeholder Impact

• Shareholders will receive $5.00 per share in cash upon completion of the acquisition.
• Employees will transition to BMS following the acquisition.
• Patients will continue to have access to Abecma through BMS.
• The acquisition will likely impact the company's partners and suppliers as BMS integrates 2seventy bio's operations.

Next Steps

• The tender offer is expected to expire on May 13, 2025.
• BMS will acquire all remaining shares of 2seventy bio common stock through a second-step merger at $5.00 per share following the successful closing of the tender offer.
• The acquisition is expected to close in the second quarter of 2025.

Key Dates

Keywords

2seventy bio, Bristol Myers Squibb, Acquisition, Abecma, Financial Results, Tender Offer, Merger, Cell Therapy, Multiple Myeloma